Michael D. Wortley
Net Worth
Last updated:
What is Michael D. Wortley net worth?
The estimated net worth of Mr. Michael D. Wortley is at least $29,704,272 as of 16 Aug 2023. He has earned $25,140,672 from insider trading and has received compensation worth at least $4,563,600 in Reata Pharmaceuticals, Inc..
What is the salary of Michael D. Wortley?
Mr. Michael D. Wortley salary is $760,600 per year as Executive Vice President & Chief Legal Officer in Reata Pharmaceuticals, Inc..
How old is Michael D. Wortley?
Mr. Michael D. Wortley is 77 years old, born in 1948.
What stocks does Michael D. Wortley currently own?
As insider, Mr. Michael D. Wortley owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Reata Pharmaceuticals, Inc. (RETA) | Executive Vice President & Chief Legal Officer | 49,701 | $0 | $0 |
What does Reata Pharmaceuticals, Inc. do?
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Michael D. Wortley insider trading
Reata Pharmaceuticals, Inc.
Mr. Michael D. Wortley has made 10 insider trades between 2019-2023, according to the Form 4 filled with the SEC. Most recently he sold 398 units of RETA stock worth $67,167 on 16 Aug 2023.
The largest trade he's ever made was exercising 51,429 units of RETA stock on 11 Nov 2020. As of 16 Aug 2023 he still owns at least 49,701 units of RETA stock.
Reata Pharmaceuticals key executives
Reata Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Colin J. Meyer (46) Executive Vice President and Chief R&D Officer
- Mr. J. Warren Huff (71) Chairman, Chief Executive Officer & Pres
- Mr. Manmeet Singh Soni (47) Chief Operating Officer, Chief Financial Officer & Executive Vice President
- Mr. Michael D. Wortley (77) Executive Vice President & Chief Legal Officer
- Ms. Dawn Carter Bir (54) Executive Vice President & Chief Commercial Officer